Review follows rapid growth in product portfolio Read More »

Safe Rx announced its availability in selected California locations of The Medicine Shoppes, a leading franchised pharmacy store banner. Read More »

Xynomic Pharmaceuticals, Inc. ("Xynomic"), a clinical stage US-China oncology drug development company, and Bison Capital Acquisition Corporation (Nasdaq: BCAC), jointly announced that Xynomic and its collaborators will present at the American Society of Clinical Oncology ("ASCO") 2019 Annual Meeting to be held in Chicago from May 31, 2019 - June 4, 2019. Read More »

New data presented and simultaneously published in the Journal of the American College of Cardiology show treatment with MitraClip resulted in significant and sustained long-term quality-of-life improvements compared to medical therapy Read More »

Partnership to raise awareness of the increased burden of heart failure in African Americans and shed light on approaches to managing the unique challenges facing this patient community Read More »

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) presented new Phase 2 data from its investigative drug candidates etrasimod, a next-generation, oral, selective sphingosine 1 phosphate (S1P) receptor modulator in development for the treatment of moderate to severely active ulcerative colitis (UC), and olorinab, a peripherally restricted, highly selective, full agonist of the cannabinoid receptor type 2 (CB2) in development for the treatment of visceral pain associated with gastrointestinal (GI) diseases, at the 14th Congress of European Crohn's and Colitis Organisation (ECCO). Read More »

Synergy Pharmaceuticals Inc. (NASDAQ: SGYP) (the "Company" or "Synergy"), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today confirmed that the previously announced sale of certain assets to Bausch Health Companies Inc. is now complete. Read More »

Daiichi Sankyo Europe (hereafter, Daiichi Sankyo) and Esperion Therapeutics Inc. (hereafter, Esperion) announced today the validation of the Marketing Authorisation Application (MAA) for bempedoic acid and the bempedoic acid / ezetimibe fixed dose combination tablet by the European Medicines Agency (EMA) Read More »

Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced the U.S. launch of Buprenorphine and Naloxone Sublingual Film, 8 mg/2 mg and 12 mg/3 mg, a generic version of Indivior's Suboxone® Sublingual Film. Read More »

This is the latest step by the companies to help make Praluent more accessible and affordable for appropriate patients Read More »

Gig Harbor, WA, location to host patient clinic and research laboratory on-site Read More »

Safe Rx announced its product availability in AmerisourceBergen, with merchandising kits available to all AmerisourceBergen California customers. Read More »

SOPHiA GENETICS, a leading health tech company, announced the closing of a $77 million investment round to accelerate the democratization of Data-Driven Medicine. Read More »

Mylan achieves key milestone to provide U.S. diabetes patients with more affordable generic version of Sanofi's Lantus® insulin glargine vials Read More »

Fimbrion Therapeutics, Inc. announced that under its joint research collaboration with GSK, researchers have identified an orally available, small molecule development candidate for the treatment and prevention of urinary tract infections (UTIs). Read More »

Ensuring the safety of our nation’s drug supply is a cornerstone of our consumer protection mission. Read More »

Concordia International Corp. ("Concordia" or "the Company") (TSX: CXR), today announced that shareholders voted in favour of a special resolution authorizing the Company to amend its articles to change its name from Concordia International Corp. to ADVANZ PHARMA Corp. Read More »

AbbVie (NYSE: ABBV) announced today patent license agreements with Pfizer over its proposed biosimilar adalimumab product. Read More »

Mylan Initiates Voluntary Nationwide Recall of 15 Lots of Valsartan Tablets, USP, Amlodipine and Valsartan Tablets, USP, and Valsartan and Hydrochlorothiazide Tablets, USP, Due to the Detection of Trace Amounts of NDEA (N-Nitrosodiethylamine) Impurity Found in the Active Pharmaceutical Ingredient Read More »

Arixa Pharmaceuticals issued the following announcement on Nov. 12.Arixa Pharmaceuticals™, Inc., a company dedicated to developing oral antibiotics for drug-resistant Gram-negative infections, today announced publication of a paper describing the chemistry of its oral prodrug of avibactam, a previously intravenous (IV)-only beta lactamase inhibitor (BLI). Read More »